Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Verzura

Psychiatry Miami Beach, FL Doctor of Osteopathy

NPI 1932690278 CMS profile 5705065

4300 Alton Rd, Miami Beach, FL 33140

Open in the dashboard

General payments

$9,307

355 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Verzura of Miami Beach, FL is reported in the CMS Open Payments database as having received $9,307 across 355 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,171 47
2024 General $2,446 94
2023 General $2,830 108
2022 General $1,080 53
2021 General $1,598 46
2020 General $62 3
2019 General $121 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Verzura
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Melissa Verzura were reported at $1,171. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Melissa Verzura Psychiatry median Middle half National median
2019 $121 $184 $59–$605 $163
2020 $62 $119 $36–$372 $114
2021 $1,598 $143 $43–$576 $132
2022 $1,080 $153 $50–$590 $149
2023 $2,830 $170 $56–$651 $160
2024 $2,446 $179 $57–$673 $164
2025 $1,171 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,492 66 payments
  2. Otsuka America Pharmaceutical, Inc. $1,138 41 payments
  3. ITI, Inc. $1,083 33 payments
  4. Teva Pharmaceuticals USA, Inc. $995 31 payments
  5. Alkermes, Inc. $783 33 payments
  6. Eisai Inc. $530 16 payments
  7. Idorsia Pharmaceuticals US Inc $515 21 payments
  8. Indivior Inc. $459 19 payments
  9. Axsome Therapeutics, Inc. $407 13 payments
  10. Vanda Pharmaceuticals Inc. $373 14 payments
  11. Other $1,532 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,307 355 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $1,455 64 payments
  2. CAPLYTA $979 29 payments
  3. REXULTI $871 34 payments
  4. LYBALVI $730 30 payments
  5. ARISTADA Cns $658 32 payments
  6. ARISTADA Cns $658 32 payments
  7. UZEDY $653 17 payments
  8. Leqembi $533 16 payments
  9. QUVIVIQ $515 21 payments
  10. ARISTADA Cns $482 23 payments
  11. Other $5,392 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

3,204

Median for Psychiatry: 574

Drug cost

$156,871

Median for Psychiatry: $27,624

Branded share of claims

15.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 16 $30,035
Leqembi Lecanemab-Irmb Brand 11 $19,172
Namzaric Memantine Hcl/Donepezil Hcl Brand 14 $17,896
Galantamine Er Galantamine Hbr Brand 169 $17,153
Memantine Hcl Er Memantine Hcl Brand 140 $13,064
Memantine Hcl Generic 298 $9,275
Rivastigmine Generic 43 $8,415
Quetiapine Fumarate Generic 196 $5,955
Donepezil Hcl Generic 399 $5,246
Sertraline Hcl Generic 645 $4,862

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$98,306

Medicare's payments for the services billed

Medicare patients

413

Average age 77

Services billed

957

232 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 70%
Arthritis 56%
Depression 54%
Ischemic heart disease 35%
Diabetes 27%
Chronic kidney disease 23%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $337
  • Lundbeck LLC $64
$401 16 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $344
$344 — —
Auvelity
  • Axsome Therapeutics, Inc. $236
$236 — —
Leqembi
  • Eisai Inc. $222
$222 11 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $211
$211 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

355 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record